Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

NCT05955508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • Hospital Clinico Universitario Santiago de Compostela Santiago de Compostela, A Coruna, Spain
  • Hospital Universitario Virgen de las Nieves Granada, Andalusia, Spain
  • Hospital Universitari Son Llatzer Palma Mallorca, Balearic Islands, Spain
  • Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
View all 17 locations
View Trial Details
Active, Not Recruiting

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma

NCT05208086

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Ch Annecy Genevois Annecy, France
  • Centre Hospitalier Métropole de Savoie Chambéry, France
  • CHU François Mitterand Dijon, France
  • CH de Dunkerque Dunkirk, France
View all 18 locations
View Trial Details
Active, Not Recruiting

Edwards EVOQUE Eos MISCEND Study

NCT02718001

Conditions
Cardiovascular Diseases, Deglutition Disorders, Digestive System Diseases, +22 more
Locations
  • Sutter Mills-Peninsula Burlingame, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • Kaiser Permanente San Francisco San Francisco, California, United States
  • Emory University Hospital/Emory University Hospital Midtown Atlanta, Georgia, United States
View all 19 locations
View Trial Details
Active, Not Recruiting

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

NCT04450173

Conditions
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, +13 more
Locations
  • University of California, San Francisco (UCSF) Fresno Fresno, California, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • University of California, San Diego San Diego, California, United States
View Trial Details
Active, Not Recruiting

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

NCT04911478

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Blood and Marrow Transplant Program Palo Alto, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Baylor Scott & White Research Institute Dallas, Texas, United States
  • MD Anderson Caner Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • City of Hope National Medical Center /ID# 273338 Duarte, California, United States
  • Valkyrie Clinical Trials /ID# 269935 Los Angeles, California, United States
  • Desert Regional Medical Center /ID# 272437 Palm Springs, California, United States
  • Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823 Golden, Colorado, United States
View all 176 locations
View Trial Details
Active, Not Recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • CHU UCL Namur / site Godinne Yvoir, Belgium
  • CHU de Tours - Hôpital Bretonneau Tours, Cedex 01, France
  • CHU de Montpellier Montpellier, Cedex 05, France
  • CHU d'Estaing Clermont-Ferrand, Cedex 1, France
View all 36 locations
View Trial Details

Related conditions